Acurx Pharmaceuticals Secures $2.5M Upfront in Registered Direct Offering Priced at Premium, with Potential for Additional $4.6M from Warrants

summarizeSummary

Acurx Pharmaceuticals entered into a definitive agreement for a registered direct offering and concurrent private placement, raising $2.5 million upfront at a premium to market, with potential for an additional $4.6 million from warrants, to fund working capital and general corporate purposes.

check_boxKey Events

• Secured $2.5 Million Upfront Capital

  The company entered into a Securities Purchase Agreement for a registered direct offering of 816,068 shares of common stock at $3.03 per share and pre-funded warrants to purchase 9,017 shares at $3.029 per share, totaling approximately $2.5 million in gross proceeds.

• Concurrent Private Placement of Warrants

  In a concurrent private placement, the company agreed to issue Series H common warrants to purchase up to 1,650,170 shares of common stock, with an exercise price of $2.78 per share. These warrants could generate an additional $4.6 million if fully exercised.

• Offering Priced at a Premium to Market

  The common stock and pre-funded warrants in the registered direct offering were priced at $3.03 and $3.029 per share, respectively, which is above the current market price of $2.67 per share. The Series H warrants also have an exercise price of $2.78, above the current market price.

• Proceeds for Working Capital and General Corporate Purposes

  The net proceeds from the offering are intended for working capital and other general corporate purposes, addressing the company's previously disclosed 'going concern' warning.

auto_awesomeAnalysis

Acurx Pharmaceuticals, a micro-cap life sciences company, has secured a critical capital infusion through a registered direct offering and concurrent private placement. This financing is highly significant, especially given the company's prior disclosure of a 'going concern' warning in its last annual report. The ability to raise approximately $2.5 million upfront, with the common stock and pre-funded warrants priced at a premium to the current market price, demonstrates institutional confidence and provides a vital lifeline for operations and advancing its lead antibiotic candidate. The additional potential $4.6 million from Series H warrants, also priced above the current market, further strengthens the company's financial outlook if exercised. While the offering is substantially dilutive, it addresses immediate liquidity needs and extends the company's operational runway, which is paramount for a development-stage biotech.